对 schiff 基化合物的结构,非线性光学和分子对接研究作为 AChE,BChE 和碳酸无水酶的多目标抑制剂
Oumria Kourat1,2, Nadia Benhalima2, Al-Anood M Al-Dies3
1Department of Material Sciences, Faculty of Sciences and Technology, University of Saida, Saida, Algeria.
Scientific reports
|October 6, 2025
概括
两种新的希夫基化合物显示出作为神经退行性疾病的多目标抑制剂的潜力,并具有非线性光学特性. 这些化合物表现出有希望的类似药物的特性和对关键酶的高抑制活性.
科学领域:
- 计算化学的计算化学
- 药用化学 医学化学
- 材料科学 材料科学 材料科学
背景情况:
- 神经退行性疾病与关键的代谢酶有关.
- 希夫基是具有多种应用的多功能有机化合物.
- 对于多目标抑制和先进材料,需要新的化合物.
研究的目的:
- 研究两种新型希夫基化合物 (BPhIM和APhIM) 的结构,电子和抑制性质.
- 评估它们作为神经退行性疾病相关酶的多目标抑制剂的潜力.
- 评估它们的非线性光学 (NLO) 特性和药物相似性.
主要方法:
- 密度函数理论 (DFT) 对结构性和电子性质的计算.
- 分子静电电位 (MEP) 和RDG分析,以获得相互作用洞察力.
- 对ACHE,BCHE,hCA I和hCA II进行分子对接模拟.
- 在 silico ADMET 分析中用于药物相似性评估.
主要成果:
- DFT揭示了低能量差距和显著的第一个超极化性,表明高反应性和NLO活动.
- 分子对接显示出有前途的结合亲缘关系,APhIM在AChE和BChE上表现优于Tacrine.
- BPhIM显示出对hCA I的强烈抑制活性.
- 在基中,ADMET的分析表明,它具有良好的药物相似性和低毒性.
结论:
- 研究的希夫基具有作为NLO材料和多目标治疗剂的双重潜力.
- 这些化合物代表了光电子学和神经退行性疾病中药物发现的有希望的支架.
- 需要进一步的研究来探索它们的治疗和物质应用.
相关概念视频
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
912
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
912
Ligand Binding and Linkage
5.5K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.5K
Noncovalent Attractions in Biomolecules
63.2K
Noncovalent attractions are associations within and between molecules that influence the shape and structural stability of complexes. These interactions differ from covalent bonding in that they do not involve sharing of electrons.
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
Four types of noncovalent interactions are hydrogen bonds, van der Waals forces, ionic bonds, and hydrophobic interactions.
Hydrogen bonding results from the electrostatic attraction of a hydrogen atom covalently bonded to a strong-electronegative atom like oxygen,...
63.2K
Enzyme Inhibition
91.5K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
91.5K
Cooperative Allosteric Transitions
8.6K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.6K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.5K


